The equine herpesvirus-1 vaccine is a critical tool for protecting horses against a pathogen responsible for respiratory disease, abortion, and devastating neurological conditions. Understanding the nuances of this vaccine, including its different types, efficacy, and role within a broader biosecurity strategy, is essential for any horse owner or manager. This overview provides a detailed look at the practical aspects of managing EHV-1 through vaccination.
Understanding EHV-1 and Its Impact on Equine Health
Equine herpesvirus-1 is a highly contagious pathogen that circulates widely within the equine population. Initial infection often presents as a mild respiratory illness characterized by fever, nasal discharge, and coughing. However, the virus's danger lies in its ability to become latent, hiding within the nervous tissue and reactivating later in response to stress. Reactivation can lead to abortion storms in pregnant mares or, in its most feared form, equine herpesvirus myeloencephalopathy (EHM), a form of neurological herpes that causes ataxia, weakness, and incontinence.
Core Vaccination Types and Their Specific Uses
Not all equine herpesvirus-1 vaccines are created equal, and the choice between them depends on the primary goal of protection. Modified live vaccines (MLV) are generally preferred for healthy, non-pregnant horses due to their ability to stimulate strong, rapid cellular immunity against the respiratory form of the disease. In contrast, inactivated or killed vaccines are the standard of care for pregnant mares, typically administered in the fifth, seventh, and ninth months of gestation to protect against abortion caused by viral reactivation. Some newer recombinant vector vaccines combine EHV-1 with other disease components, offering broader protection with fewer injections.
Vaccine Efficacy and the Challenge of Neurological Protection
While vaccination significantly reduces the severity and duration of respiratory shedding, it is important to manage expectations regarding protection against the neurological form of the disease. Current vaccines are highly effective at preventing the initial respiratory signs and limiting the viral load shed by infected animals, which is crucial for breaking transmission chains. However, they may provide only partial protection against EHM, meaning that vaccinated horses can still develop neurological signs in the event of a high-dose exposure or a mutated strain. This underscores that vaccination is a component of risk reduction, not an absolute shield.
Strategic Vaccination Scheduling and Protocols
Implementing an effective schedule requires balancing the need for immunity with practical management. For adult horses with low exposure risk, an annual booster is often sufficient to maintain baseline immunity. Horses in frequent competition, shows, or those with a history of respiratory issues often benefit from a twice-yearly schedule, particularly before high-stress events like transport or intensive training. For broodmares, the protocol is strictly timed to align with the fetal developmental stages where the risk of abortion is highest, ensuring maternal antibodies are transferred to the foal via colostrum.
The Role of Vaccination within a Biosecurity Framework
Vaccination alone cannot prevent an outbreak, particularly in environments with high horse turnover. The most successful EHV-1 management programs integrate vaccination with rigorous biosecurity measures. These include isolating new arrivals for a minimum of 30 days, implementing strict hand-washing and equipment disinfection protocols between groups, and minimizing nose-to-nose contact at events. During an outbreak, veterinarians may recommend an "emergency" vaccination strategy using modified live vaccines to try to stimulate a rapid response in exposed, unvaccinated horses, highlighting the dynamic role of the vaccine in crisis management.
